Pharmacyclics
Pharmacyclics is an AbbVie-owned biopharmaceutical subsidiary developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with IMBRUVICA (ibrutinib) as its primary approved product across CLL, MCL, WM, MZL, FL, and cGVHD indications.
- Company typePrivate
- Founded1991
- HeadquartersSunnyvale, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pharmacyclics does
Pharmacyclics LLC is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, and a wholly-owned subsidiary of AbbVie following a 2015 acquisition valued at approximately $21 billion. The company focuses on discovering and developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with its core technology centered on Bruton's tyrosine kinase (BTK) inhibition through ibrutinib. Pharmacyclics operates one of the most robust clinical oncology development programs for a single molecule in the industry, having sponsored more than 50 clinical trials including 18 Phase 3 studies over 11 years. Its primary commercial product, IMBRUVICA (ibrutinib), is approved by the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic graft-versus-host disease (cGVHD), and mature B-cell non-Hodgkin lymphomas in previously treated pediatrics.
The company also collaborates on venetoclax (VENCLYXTO), a Bcl-2 inhibitor approved for CLL in combination regimens. Its primary customer segments are patients with hematologic malignancies and immune-mediated diseases, the oncologists and hematologists who prescribe IMBRUVICA, and clinical researchers participating in investigator-initiated studies. Pharmacyclics generates revenue indirectly through AbbVie's global commercial infrastructure, distributing IMBRUVICA via retail, hospital, and specialty pharmacies under prescription. The company supplements its commercial offering with the IMBRUVICA by Your Side patient support program, a medical information portal, and a Medical Education Grants Program covering CLL, Waldenstrom's Macroglobulinemia, and cGVHD. As a private subsidiary, Pharmacyclics does not disclose standalone financial results; its revenues are consolidated into AbbVie's reporting, with no information available on segment-level revenue, pricing, or churn metrics.
Pharmacyclics firmographics
Firmographics- Name
- Pharmacyclics
- Legal name
- Pharmacyclics LLC
- Website
- https://pharmacyclics.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Pharmacyclics is an AbbVie-owned biopharmaceutical subsidiary developing small-molecule drugs for hematologic malignancies and immune-mediated diseases, with IMBRUVICA (ibrutinib) as its primary approved product across CLL, MCL, WM, MZL, FL, and cGVHD indications.
- Ownership category
- akta.pro rank
Pharmacyclics industry classification
Industry- Product category
- Hematology Oncology Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)
Keywords
Where Pharmacyclics is headquartered
LocationHeadquarters
- HQ city
- Sunnyvale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pharmacyclics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Distribution channels1 record
Marketing channels5 records
Pharmacyclics product offering
Product offeringCore offering
Pharmacyclics develops and commercializes IMBRUVICA (ibrutinib), a first-in-class Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of multiple hematologic malignancies including CLL/SLL, MCL, WM, MZL, FL, cGVHD, and pediatric mature B-cell non-Hodgkin lymphomas. The company also participates in the development of venetoclax (VENCLYXTO), a Bcl-2 inhibitor for CLL. Distribution occurs through AbbVie's pharmaceutical commercial infrastructure via healthcare provider prescriptions.
Product overview
Pharmacyclics is an AbbVie company that develops and commercializes cancer and immune-mediated disease treatments. The company's primary product is IMBRUVICA (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, supplemented by patient support programs and medical education initiatives. The company operates one of the most robust clinical oncology development programs for a single molecule, with over 50 company-sponsored clinical trials including 18 Phase 3 studies. Key therapeutic areas include chronic lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), and chronic graft-versus-host disease (cGVHD).
Differentiator
Problem solved
Functional benefit
Brands
- IMBRUVICA: Ibrutinib - Bruton's tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström's Macroglobulinemia, marginal zone lymphoma, and chronic graft-versus-host disease.
Products and services
- IMBRUVICA (ibrutinib) Bruton's tyrosine kinase (BTK) inhibitor approved for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic graft-versus-host disease (cGVHD), and mature B-cell non-Hodgkin lymphomas in pediatrics. Prescribed by oncologists and hematologists.
- Venetoclax (VENCLYXTO) Bcl-2 inhibitor developed in collaboration, approved for CLL treatment in combination regimens. Used by oncologists and hematologists for chronic lymphocytic leukemia therapy.
Companies that use Pharmacyclics
Customer profileSegments3 records
Ideal customer profiles2 records
Pharmacyclics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pharmacyclics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AbbViecorePharmacyclics is a wholly-owned subsidiary of AbbVie, headquartered in the Bay Area. AbbVie acquired Pharmacyclics in 2015. Pharmacyclics operates under AbbVie's corporate structure while maintaining its brand identity and focus on oncology and immunology. All legal, privacy, and corporate governance references point to AbbVie as the parent entity.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Pharmacyclics competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Major oncology incumbent with hematology assets (e.g., Bosulif, Mektovi) that address the same prescriber base of hematologists treating CLL and other B-cell malignancies.
- Gilead Sciences: Competes in B-cell hematologic malignancies via its Kite cell therapy franchise (Yescarta, Tecartus) and Trodelvy in ADC oncology. Same treating-physician customer base as IMBRUVICA.
- AbbVie: Pharmacyclics' parent company and the acquirer in the 2015 ~$21B deal. AbbVie is the broader specialty pharma incumbent that owns and commercializes the IMBRUVICA franchise.
- Bristol-Myers Squibb: Major oncology player with a hematology portfolio (e.g., Revlimid, Reblozyl, Pomalyst) overlapping the same customer base of hematologists treating CLL, MDS, and other blood cancers.
- Novartis: Major oncology and hematology player with therapies in CLL and B-cell malignancies (e.g., Kymriah, Scemblix). Comparable institutional customer base and indication overlap.
- Roche: Global oncology leader with a broad hematology and lymphoma franchise (including Rituxan legacy and Polivy). Comparable customer base of oncologists and hematologists treating B-cell malignancies.
Direct peers
- AstraZeneca: Markets Calquence (acalabrutinib), a second-generation BTK inhibitor that directly competes with IMBRUVICA in CLL and other B-cell malignancies. Highly comparable mechanism, indication overlap, and customer base.
- BeiGene: Markets Brukinsa (zanubrutinib), a next-generation BTK inhibitor approved across multiple B-cell malignancies. Direct competitor to IMBRUVICA in CLL, MCL, MZL, WM, and FL.
- Eli Lilly: Markets Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor acquired via the Loxo transaction. Competes in the same BTK inhibitor class and hematology indications as Pharmacyclics.
Others
- Johnson & Johnson: Historically co-developed and co-promoted IMBRUVICA with Pharmacyclics / AbbVie. Compares as a legacy commercialization partner in the same BTK franchise and a broader oncology competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Pharmacyclics social profiles
Digital presencePharmacyclics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharmacyclics leadership team
Management profileNumber of profiles
Profiles5 records
Pharmacyclics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharmacyclics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharmacyclics
What does Pharmacyclics do?
Pharmacyclics develops and commercializes IMBRUVICA (ibrutinib), a first-in-class Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of multiple hematologic malignancies including CLL/SLL, MCL, WM, MZL, FL, cGVHD, and pediatric mature B-cell non-Hodgkin lymphomas. The company also participates in the development of venetoclax (VENCLYXTO), a Bcl-2 inhibitor for CLL. Distribution occurs through AbbVie's pharmaceutical commercial infrastructure via healthcare provider prescriptions.
Is Pharmacyclics a public or private company?
Pharmacyclics is a private company. It is classified as corporate owned and is currently operating.
When was Pharmacyclics founded?
Pharmacyclics was founded in 1991. It employs 501 to 1,000 people.
Where is Pharmacyclics based?
Pharmacyclics is headquartered in Sunnyvale, United States, in the North America region.
Who are Pharmacyclics's main competitors?
Broad incumbents on record are Pfizer, Gilead Sciences, AbbVie, Bristol-Myers Squibb, Novartis and Roche. Direct peers are AstraZeneca, BeiGene and Eli Lilly. Johnson & Johnson is listed as an others.
Does Pharmacyclics have an API?
No public API is recorded for Pharmacyclics.
What industry is Pharmacyclics in?
Pharmacyclics's product category is Hematology Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its SIC code is 2834.